Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a ... under priority review in bladder cancer. German Merck and Pfizer ...

The Phase 3 clinical trial showed that enfortumab vedotin in combination with pembrolizumab nearly doubled median overall survival (OS) and signficantly ... of advanced bladder cancer treatment ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

Oct. 9, 2024 — How bladder cancer originates and progresses has been illuminated as never before. Researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key ...

After this a trans urethral resection of Bladder Tumour [TURBT] is ... If they do well, they are given maintenance Avelumab therapy. However, if cancer progresses, either second line chemotherapy ...

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

There are many treatment options for bladder cancer, which vary depending on the stage and type of bladder cancer you have, your overall health, and your preferences. These include various types ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...